Author

Rui Qu

Memorial Sloan Kettering Cancer CenterORCID 0009-0009-1185-9076Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Rui Qu2 papers · Hong Kong University of Science and Technology

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Alex KentsisiD· 1 shared Andrea CalifanoiD· 1 shared Andrew L. KungiD· 1 shared Daniel CameroniD· 1 shared Elisa de StanchinaiD· 1 shared Filemon S. Dela CruziD· 1 shared Helen S. MuelleriD· 1 shared Mrinal M. GounderiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alex KentsisORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologyJournal of Clinical InvestigationPeer-reviewedAug 12, 2025

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomas

Yaniv Kazansky, Helen S. Mueller, Daniel Cameron…·Alex Kentsis

The paper identifies ATR as a target for combination EZH2 epigenetic therapy in SMARCB1-deficient sarcomas, showing that EZH2 inhibition promotes DNA damage via PGBD5, and that ATR inhibition enhances therapeutic responses.

8 citations

humanbulk RNA-seq

𝕏 PostBluesky